Skip to content

Quality of Life in Chinese Working and School Age Population With MDD

A Survey of Quality of Life in Chinese Working and School Age Population With Major Depressive Disorder

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04986124
Enrollment
500
Registered
2021-08-02
Start date
2021-04-01
Completion date
2021-08-30
Last updated
2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder, Remission

Keywords

cognitive function, social function, quality of life, working and school age population

Brief summary

Major depressive disorder (MDD) is a common mental illness with high prevalence and global burden. Previous studies revealed that over 70% patients in remission still had decreased quality of life, severe function impairment, low positive mental health score and poor coping ability. However, few studies focus on working and school age patients with MDD. A GBD survey showed that over 40% MDD patients are 15-50 years old. Therefore, we initiate the present multi-center cross-sectional survey to investigate the associations between clinical symptoms, cognitive function, occupational/study ability, and quality of life in Chinese working and school age population with MDD who are in remission.

Detailed description

This is a multi-center cross-sectional study. Patients with MDD who received medication treatment and achieved remission for at least 8 weeks will be enrolled. For all the participants, demographic information will be collected; clinical symptoms, cognitive function, occupational/study ability, and quality of life will be evaluated by using 17-items HAMD, PHQ-9, HAMA, PSQI, SHAPS, HCL-32, SDS, LEAPS, QOL-6, PFQ and THINC-it toolkit.

Interventions

OTHERtreatment as usual

No inervention. Treatment regime remains unchanged.

Sponsors

Beijing HuiLongGuan Hospital
CollaboratorOTHER
Huaxi Hospital
CollaboratorOTHER
Second Xiangya Hospital of Central South University
CollaboratorOTHER
Nanjing Brain Hospital, Nanjing Medical University
CollaboratorUNKNOWN
Guangzhou Psychiatric Hospital
CollaboratorOTHER_GOV
First Affiliated Hospital Xi'an Jiaotong University
CollaboratorOTHER
Shanghai Mental Health Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Out-patients; * Men or women aged between 16 and 50, with junior high school education or above; * According to medical history, patients should be diagnosed with major depressive episode by two or above psychiatric doctors based on ICD-10 criteria; * According to assessment, patients should meet the DSM-5 criteria for MDD when in past episodes; * Patients received stable ant-depression medication treatment for at least 8 weeks before enrolment; * 17-item HAMD total score ≤ 7; * Willing to participate in this study, and sign an informed consent.

Exclusion criteria

* HCL-32 total score \< 12; * Diagnosed with bipolar disorder; * Suffering from some serious physical diseases (e.g. moderate or severe brain injury, central nervous system diseases, or other unstable physical condition affecting the whole body) adversely affects the performance on neuropsychological test or rating scales; * Received ECT in the past 6 months.

Design outcomes

Primary

MeasureTime frameDescription
The Sheehan disability scale (SDS)up to 1 weeksTo evaluate the functional impairment, including work/study, daily life and family responsibility. The score of each subscale ranged from 0 to 10 which means from no impairment to loss of function.
Quality of Life, short form 6 (QOL-6)up to 4 weeksTo evaluate the quality of life in patients with MDD. The higher the total score, the better the quality of life.
The Psychosocial Function Questionnaire in Patients with Depression (PFQ)up to 1 weeksTo evaluate the psychosocial function of patients with MDD. The lower total score means the severer psychosocial function impairment.

Secondary

MeasureTime frameDescription
The Hamilton Anxiety Scale (HAMA)up to 1 weeksTo evaluate the severity of anxiety symptoms by clinicians. The total score \< 6: no anxiety sympotom.
Pittsburgh Sleep Quality Index (PSQI)up to 4 weeksTo evaluate the sleep quality. The lower the total score, the better sleep quality (\<5).
The Lam Employment Absence and Productivity Scale (LEAPS)up to 2 weeksTo evaluate the work capacity. The higher total score means the severer impairment of work capacity.
THINC-it toolkitup to 1 weeksTo assess the cognitive function in patients with MDD specifically. The composite THINC-it tool score is the integrated total score of results from performance on five sub-component cognitive tests of the THINC-it tool.
The Snaith-Hamilton Pleasure Scale (SHAPS)up to 4 weeksTo evaluate the severity of anhedonia. The higher total score means the severer of anhedonia.
The Hamilton Depression Scale-17 items (HAMD)up to 1 weeksTo evaluate the severity of depressive symptoms by clinicians. Remission: total score \< 7.
Patient Health Questionnaire-9 (PHQ-9)up to 2 weeksto evaluate the severity of depressive symptoms by patients. Remission: total score \< 4.

Countries

China

Contacts

Primary ContactJun Chen, M.D., Ph.D
doctorcj2010@gmail.com021-34773367
Backup ContactTao Yang, M.D.
yangtao2015sjtu@foxmail.com+86 15800579832

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026